BMY Bristol-Myers Squibb
- 44.090
- +0.390+0.89%
Bristol-Myers Squibb News
Express News | NYSE Order Imbalance 185345.0 Shares on Sell Side
Schrodinger Gets Rights to Cancer Drug Candidate Back From Bristol
Bristol-Myers Squibb Options Spot-On: On May 1st, 86,619 Contracts Were Traded, With 572.34K Open Interest
On May 1st ET, $Bristol-Myers Squibb(BMY.US)$ had active options trading, with a total trading volume of 86,619 options for the day, of which put options accounted for 80.29% of the total transactions
Express News | NYSE Order Imbalance 332707.0 Shares on Buy Side
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50
Bristol-Myers Squibb (BMY) has an average hold rating and a price target range of $37 to $75, according to analysts polled by Capital IQ. Price: 44.29, Change: +0.35, Percent Change: +0.80
Express News | Editas Medicine Inc: Extension Also Has Options to Extend Collaboration for up to an Additional Two Year
Express News | Editas:2 Yr Extension Collaboration With Bristol Myers,Parties May Research, Develop,Commercialize Autologous, Allogeneic Alpha-Beta T Cell Medicines
Express News | Editas Medicine Inc: Under Collaboration, Bristol Myers Squibb Has Opted Into 13 Different Programs Across 11 Gene Targets to Date
Express News | Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Stifel, Morgan Stanley Bullish on Newly Public Contineum
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 9 unusual trades.Delving into the details, w
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript
Express News | Scenic Biotech Enters Into Research Collaboration With Bristol Myers Squibb
Japan's Ono Pharma Says $2.4 Bln Deciphera Purchase 'First Step' for Global Expansion
The world's first myocardial myosin inhibitor, mevantul (mavacitai capsules) was approved in China
It is used to treat adult patients with obstructive hypertrophic cardiomyopathy as a myocardial myosin inhibitor. It targets the core pathophysiological mechanism of the disease, reduces excessive myocardial contraction by reducing the formation of excessive myosin and actin crossbridges, and improves relaxation function. Key global and Chinese phase III clinical studies EXPLORER-HCM and EXPLORER-CN show that in Chinese patients with obstructive hypertrophic cardiomyopathy (OHCM) [1], Meavant can significantly improve left ventricular outflow (LVOT) pressure differences at rest or Valsalva stimulation, New York Heart Association (N)
Johnson & Johnson, Bristol-Myers Squibb lose lawsuit in US drug price negotiation process
A US judge on Monday dismissed a challenge by Bristol Myers Squibb (Bristol Myers Squibb) and Johnson & Johnson (Johnson & Johnson) to a law requiring the two companies to negotiate with the US government's health insurance plan (Medicare) about the price of their blockbuster products to prevent blood clots; otherwise, they will face heavy penalties.
Express News | NYSE Order Imbalance 1488687.0 Shares on Buy Side
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 5.98% since its last report. The company recently reported that it has 35.12 million shares sold short, which is 1.73% of all regula
Jumo Health to Lead a Roundtable Discussion on Authenticity and the Patient Voice at the Annual Health Equity in Clinical Trials Congress
NEW HAVEN, Conn., April 29, 2024 /PRNewswire/ -- Jumo Health—a global provider of age-appropriate, culturally relevant medical education—today announced that Kevin Aniskovich, the Company's President
Earnings Call Summary | Bristol-Myers Squibb(BMY.US) Q1 2024 Earnings Conference
The following is a summary of the Bristol-Myers Squibb Company (BMY) Q1 2024 Earnings Call Transcript:Financial Performance:Bristol-Myers Squibb Company reported a strong Q1 in 2024 with significant g
Analysis
Price Target
No Data
